# Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT01211002** · PHASE4 · UNKNOWN · sponsor: **Simcere Pharmaceutical Co., Ltd** · enrollment: 170 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **RADIATION:** radiotherapy combined with EP
- **DRUG:** radiotherapy / EP combined with recombinant human endostatin

## Key facts

- **NCT ID:** NCT01211002
- **Lead sponsor:** Simcere Pharmaceutical Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-10
- **Primary completion:** 2011-12
- **Final completion:** 2012-12
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2010-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01211002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01211002, "Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01211002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*